In this study, we selected 78 lung cancer patients harboring MET fusions, including 56 patients from the Burning Rock® LAVA database (P.R. China) and 22 patients from the cBioPortal of Cancer Genomics (the cBioPortal) database [21, 22], to elucidate the incidences and types of MET fusions, the responses to treatment, and the concomitant genomic alterations in lung cancer patients harboring primary or acquired MET fusions. The gene discussed is MET; the disease is lung cancer.